ICCM:NASDAQ, IceCure Medical Ltd
ICCM stock overview
IceCure Medical Ltd (ICCM:NASDAQ) closed at $0.760 on November 16, 2026,
up 4.12% on the day.
The stock trades 96.6% below its 52-week high of $22.50
and 16.9% above its 52-week low of $0.650.
Over the past year, it lost 96.5%.
IceCure Medical Ltd is part of the Health Care sector.
Key figures
- Price
- $0.760
- Day change
- +4.12%
- Volume
- 202,290
- Average volume
- 155,732
- Market cap
- 3M+
- 52-week range
- $0.650 – $22.50
- 50-day average
- $1.35
- 200-day average
- $6.99
Price action over the past year
In 252 trading sessions since November 14, 2025, ICCM closed higher on 97 days (38%).
Its best day was June 17, 2026 (+200.47%) and its worst was March 26, 2026 (-33.67%).
The stock moved 10% or more in a single session 22 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
ICCM news
-
Nov 12, 2026:
HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates
-
Nov 11, 2026:
IceCure Heads Into Seasonally Soft Q3 Needing Proof That CHOICE Enrollment And US Installs Are Real
-
Nov 11, 2026:
IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026
-
Nov 9, 2026:
IceCure Medical Secures New Chinese Patent for Cryogenic Technology Connector
-
Nov 9, 2026:
IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio
-
Nov 6, 2026:
Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates
-
Oct 27, 2026:
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
-
Oct 21, 2026:
IceCure enrols initial patients for ProSense cryoablation trial in US
About IceCure Medical Ltd
Icecure Medical Ltd is a Israel based firm which develops and markets minimally invasive cryoablation therapies for women's health. The company provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma.
Similar stocks
Find more stocks like ICCM with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.